AQR Capital Management LLC Invests $131,000 in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

AQR Capital Management LLC acquired a new position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 56,551 shares of the company’s stock, valued at approximately $131,000. AQR Capital Management LLC owned 0.08% of Ventyx Biosciences at the end of the most recent quarter.

A number of other large investors have also modified their holdings of VTYX. Farallon Capital Management LLC purchased a new stake in shares of Ventyx Biosciences during the first quarter worth $17,435,000. Redmile Group LLC grew its stake in shares of Ventyx Biosciences by 944.4% during the first quarter. Redmile Group LLC now owns 2,164,126 shares of the company’s stock worth $11,903,000 after purchasing an additional 1,956,923 shares in the last quarter. First Light Asset Management LLC acquired a new position in shares of Ventyx Biosciences during the first quarter worth $3,437,000. Ikarian Capital LLC grew its stake in shares of Ventyx Biosciences by 8,483.8% during the first quarter. Ikarian Capital LLC now owns 507,647 shares of the company’s stock worth $2,792,000 after purchasing an additional 501,733 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new position in shares of Ventyx Biosciences during the second quarter worth $608,000. Hedge funds and other institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Stock Performance

Shares of VTYX stock opened at $2.54 on Friday. The stock’s 50-day moving average is $2.19 and its two-hundred day moving average is $3.10. The firm has a market cap of $179.50 million, a price-to-earnings ratio of -0.91 and a beta of 0.36. Ventyx Biosciences, Inc. has a 1 year low of $1.79 and a 1 year high of $17.65.

Ventyx Biosciences (NASDAQ:VTYX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.12. As a group, research analysts predict that Ventyx Biosciences, Inc. will post -2.14 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on VTYX shares. Canaccord Genuity Group lowered their target price on shares of Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Wells Fargo & Company lowered their target price on shares of Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Finally, HC Wainwright reiterated a “neutral” rating and set a $6.00 target price on shares of Ventyx Biosciences in a research note on Tuesday. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $8.29.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.